Morant S V, Pettitt D, MacDonald T M, Burke T A, Goldstein J L
Medicines Monitoring Unit, Department of Medicine & Therapeutics, University of Dundee, Ninewells Hospital & Medical School, Dundee, UK.
Pharmacoepidemiol Drug Saf. 2004 Jun;13(6):345-53. doi: 10.1002/pds.946.
To compare the relative risks of upper GI haemorrhage (UGIH) in users of Newer versus Older, non-specific NSAIDs when adjusted for channelling bias by regression on individual covariates, a propensity score and both.
Cohort study of patients prescribed NSAIDs between June 1987 and January 2000. Exposure to Newer and Older non-specific NSAIDs was identified, and risk factors evaluated for each patient. Results of multiple covariate analyses and the propensity scoring technique to assess potential channelling bias in comparisons between Newer and Older non-specific NSAIDs were compared.
This study included 7.1 thousand patient years (tpy) exposure to meloxicam, 1.6 tpy exposure to coxibs, and 628 tpy exposure to Older non-specific NSAIDs. Patients receiving Newer NSAIDs were older, more likely to have a history of GI symptoms, and at higher risk for GI complications. Adjusting for these risk factors reduced the relative risks of UGIH on meloxicam and coxibs versus Older non-specific NSAIDs to 0.84 (95%CI 0.60, 1.17) and 0.36 (0.14, 0.97) respectively.
Channelling towards high GI risk patients occurred in the prescribing of Newer NSAIDs. Propensity scores highlighted the markedly different risk profiles of users of Newer and Older non-specific NSAID. Correcting for channelling bias, coxib exposure, but not meloxicam exposure, was associated with less UGIH than Older non-specific NSAID exposure. In the present study, corrections made by regression on a propensity score and on individual covariates were similar.
通过对个体协变量、倾向得分以及两者进行回归分析来校正渠道偏倚,比较使用新型与旧型非特异性非甾体抗炎药(NSAIDs)的患者发生上消化道出血(UGIH)的相对风险。
对1987年6月至2000年1月期间开具NSAIDs处方的患者进行队列研究。确定新型和旧型非特异性NSAIDs的暴露情况,并评估每位患者的风险因素。比较了多重协变量分析结果和倾向评分技术,以评估新型与旧型非特异性NSAIDs比较中潜在的渠道偏倚。
本研究包括7100患者年(tpy)的美洛昔康暴露、160 tpy的昔布类药物暴露以及628 tpy的旧型非特异性NSAIDs暴露。接受新型NSAIDs的患者年龄更大,更有可能有胃肠道症状史,发生胃肠道并发症的风险更高。校正这些风险因素后,美洛昔康和昔布类药物相对于旧型非特异性NSAIDs发生UGIH的相对风险分别降至0.84(95%CI 0.60, 1.17)和0.36(0.14, 0.97)。
在新型NSAIDs的处方中存在向高胃肠道风险患者的渠道现象。倾向评分突出了新型和旧型非特异性NSAIDs使用者明显不同的风险特征。校正渠道偏倚后,与旧型非特异性NSAIDs暴露相比,昔布类药物暴露而非美洛昔康暴露与UGIH发生率较低相关。在本研究中,通过对倾向评分和个体协变量进行回归所做的校正相似。